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Abstract
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is a common cause of liver disease
worldwide and is a growing epidemic. A high ratio of omega-6 fatty acids to
omega-3 fatty acids in the diet has been implicated in the development of
NAFLD. However, the inflicted cellular pathology remains unknown. A high
ratio may promote lipogenic pathways and contribute to reactive oxygen species
(ROS)-mediated damage, perhaps leading to mitochondrial dysfunction.
Therefore, these parameters were investigated to understand their contribution to
NAFLD development.
AIM
To examine the effect of increasing ratios of omega-6:3 fatty acids on
mitochondrial function and lipid metabolism mediators.
METHODS
HepG2-derived VL-17A cells were treated with normal (1:1, 4:1) and high (15:1,
25:1) ratios of omega-6: omega-3 fatty acids [arachidonic acid (AA):
docosahexaenoic acid (DHA)] at various time points. Mitochondrial activity and
function were examined via MTT assay and Seahorse XF24 analyzer, respectively.
WJH https://www.wjgnet.com March 27, 2020 Volume 12 Issue 384
and license their derivative works
on different terms, provided the
original work is properly cited and
the use is non-commercial. See:
http://creativecommons.org/licen
ses/by-nc/4.0/
Manuscript source: Unsolicited
manuscript
Received: July 14, 2019
Peer-review started: July 16, 2019
First decision: November 2, 2019
Revised: December 24, 2019
Accepted: January 14, 2020
Article in press: January 14, 2020
Published online: March 27, 2020
P-Reviewer: Cheng JT, Mizuguchi
T, Niu ZS, Shimizu Y, Sitkin S
S-Editor: Dou Y
L-Editor: A
E-Editor: Wu YXJ
Triglyceride accumulation was determined by using EnzyChrom™ and levels of
ROS were measured by fluorescence intensity. Protein expression of the
mediators of lipogenic, lipolytic and endocannabinoid pathways was assessed by
Western blotting.
RESULTS
High AA:DHA ratio decreased mitochondrial activity (P < 0.01; up to 80%) and
promoted intracellular triglyceride accumulation (P < 0.05; 40%-70%).
Mechanistically, it altered the mediators of lipid metabolism; increased the
expression of stearoyl-CoA desaturase (P < 0.05; 22%-35%), decreased the
expression of peroxisome proliferator-activated receptor-alpha (P < 0.05; 30%-
40%) and increased the expression of cannabinoid receptor 1 (P < 0.05; 31%).
Furthermore, the high ratio increased ROS production (P < 0.01; 74%-115%) and
reduced mitochondrial respiratory functions such as basal and maximal
respiration, ATP production, spare respiratory capacity and proton leak (P < 0.01;
35%-68%).
CONCLUSION
High AA:DHA ratio induced triglyceride accumulation, increased oxidative
stress and disrupted mitochondrial functions. Stimulation of lipogenic and
steroidal transcription factors may partly mediate these effects and contribute to
NAFLD development.
Key words: Non-alcoholic fatty liver disease; Lipogenesis; Omega fatty acids;
Mitochondrial dysfunction; Reactive oxygen species; Oxidative stress
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: A high ratio of omega 6:3 fatty acids in the diet has been implicated in the
development of non-alcoholic fatty liver disease, a growing epidemic of major concern.
The cellular pathology induced by such high ratios remains unknown. Here, we observed
that in human hepatoma HepG2 (VL-17A) cells, high omega-6:omega-3 ratio reduced
mitochondrial activity, increased triglyceride accumulation, elevated reactive oxygen
species levels and interrupted several mitochondrial functions. Moreover, the increased
expression of stearoyl-CoA desaturase, decreased expression of peroxisome proliferator-
activated receptor alpha and elevation in cannabinoid receptor-1 expression collectively
lead to lipogenesis and lipotoxicity, which are key features of non-alcoholic fatty liver
disease development.
Citation: Ghazali R, Mehta KJ, Bligh SA, Tewfik I, Clemens D, Patel VB. High omega
arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered
lipid metabolism in human hepatoma cells. World J Hepatol 2020; 12(3): 84-98
URL: https://www.wjgnet.com/1948-5182/full/v12/i3/84.htm
DOI: https://dx.doi.org/10.4254/wjh.v12.i3.84
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) overarches all chronic liver conditions
resulting from high liver fat content that are not caused by alcohol consumption,
steatogenic medication or monogenic disorders. It encompasses a broad spectrum of
pathological states ranging from the initial steatosis (fatty liver), which may progress
to non-alcoholic steatohepatitis (NASH), followed by fibrosis and cirrhosis, and may
result in liver failure or hepatocellular carcinoma[1]. NAFLD is believed to arise in a
multi/repeated hit stage process. In the first stage, lipids (triglycerides) accumulate in
the  hepatocytes  due  to  factors  such  as  increased  consumption  of  lipids  and/or
carbohydrates, insulin resistance-induced release of free fatty acids from the adipose
tissue, elevated lipogenesis, reduced fatty acid oxidation, and reduced lipoprotein
secretion from the liver. Subsequent stages are triggered by inflammation, oxidative
stress, gut dysbiosis and mitochondrial dysfunction, which causes cellular injury
eventually leading to liver fibrosis[2,3].
The current global prevalence of NAFLD is approximately 25%[4] and a common
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cause of liver cancer in United States[1]. With the growing epidemic of obesity in the
Western world and the Middle East, NAFLD is predicted to be the most frequent
indication for liver transplantation by 2030[5]. It is also associated with the metabolic
syndrome, increasing the risk for cardiovascular disease, insulin resistance and type 2
diabetes[6].  Thus,  effective  preventive  and  prophylactic  measures  are  urgently
required.
A high omega 6: omega-3 fatty acid dietary ratio has been correlated with NAFLD
pathogenesis[7]. A normal omega 6:3 ratio is around 1-4:1, where omega-3 fatty acids
regulate  hepatic  lipogenesis  and  are  anti-inflammatory  and  anti-thrombotic[8,9].
However, Western diets contain higher omega 6:3 ratios ranging from 15-20:1[8,10] that
disrupt  the  regulation  of  intrahepatic  lipids,  and promote  a  prothrombotic  and
proinflammatory environment[10].  In NAFLD/NASH patients,  omega-3 levels are
significantly  low,  which  correlates  with  hepatic  steatosis  and  increased
proinflammatory arachidonic acid (AA) metabolic  products[11,12].  The therapeutic
effects of low dietary omega 6:3 ratio have been observed in animal models and in
clinical  trials  with  NAFLD/NASH patients[13-15].  In  this  scenario,  it  is  pivotal  to
understand the yet unknown underlying cellular mechanisms that prevail  under
states  of  high omega-6:  omega-3 ratio.  This  may identify  cellular  and molecular
targets that may help in formulating therapeutic interventions to effectively prevent
and treat NAFLD.
Accordingly, this study examined the effects of high ratio of omega-6: omega-3
fatty acids on mitochondrial functions, and several parameters and regulators of lipid
metabolism  to  understand  the  underlying  mechanisms  and  extrapolate  their
contribution to fatty liver development and NAFLD pathogenesis. Here, the effect of
high AA (omega-6): docosahexaenoic acid (DHA) (omega-3) ratio was studied on
intracellular triglyceride accumulation, mitochondrial activity, oxidative stress and
mitochondrial functions. Moreover, to understand the responses of the mechanistic
mediators, we examined the expressions of stearoyl-CoA desaturase (SCD1) - the
lipogenic enzyme involved in fatty acid synthesis, peroxisome proliferator-activated
receptor alpha (PPAR-α)- a transcription factor that mediates fatty acid oxidation,
sterol regulatory element-binding protein 1 (SREBP1c) - a transcription factor that
induces genes involved in fatty acid synthesis, and cannabinoid receptors 1 and 2
(CB1, CB2), as their activation has been implicated in fatty liver development[16,17].
MATERIALS AND METHODS
Cell culture
VL-17A,  human  hepatoma  cell  line  (overexpress  ADH  and  CYP2E1)[18]  were
maintained at 37 ºC in 5% CO2 in a high-glucose (25 mmol) Dulbecco’s Modified Eagle
Medium (DMEM) (Lonza Ltd, United Kingdom) supplemented with L-Glutamine (2
mmol)  (Lonza Ltd,  United Kingdom),  penicillin (100 U/mL) (Lonza Ltd,  United
Kingdom),  streptomycin  (100  mg/mL)  (Lonza  Ltd,  United  Kingdom),  sodium
pyruvate (1 mmol) and 10% foetal calf serum (FCS) (Biosera, United Kingdom)[19,20].
Prior  to  maintenance,  cells  were  grown in  Plasmocin  Prophylactic  (5  µg/mL in
DMEM) for four weeks.
Treatments
Cells were treated with different ratios of omega-6 AA: omega-3 DHA (1:1, 4:1, 15:1
and 25:1) for the required period. AA and DHA were of > 98% purity and acquired
from Sigma-Aldrich (Gillingham, United Kingdom). Fatty acids were prepared as 8
mmol stock in DMSO and then diluted in 1% FCS low-glucose (1 g/L) DMEM to
obtain the required treatment concentrations[20]. The fatty acids were in free form with
a concentration of 0.02% bovine serum albumin (BSA) in the FCS[20].
Following  the  treatments,  various  parameters  were  examined  such  as
mitochondrial  activity,  triglyceride accumulation,  reactive oxygen species (ROS)
levels and mitochondrial functions (basal and maximal respiration, ATP production,
protein leak and spare respiratory capacity). Also, protein expression of the mediators
of lipogenic, lipolytic and endocannabinoid pathways, SCD1, PPAR-α, SREBP1c, CB1
and CB2 were studied. Data were expressed relative to the experimental control i.e.,
cells not treated with omega fatty acids but treated with 0.5 % DMSO in maintenance
medium (referred to as untreated control). Comparisons were drawn between the
three groups: (1) Untreated control; (2) Moderate omega-6: omega-3 ratios of 1:1 and
4:1; and (3) High ratios of 15:1 and 25:1.
Assessment of lipotoxicity
Mitochondrial  activity,  and thereby lipotoxicity,  was assessed by using the MTT
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assay,  adapted  from  previous  studies[21,22].  Briefly,  cells  (2.5  ×  104  cells/200  µL
DMEM/well)  were  incubated overnight  in  96-well  plates  and then treated with
different ratios of omega fatty acids for 24, 48 and 72 h. After the treatment, MTT (5
mg/mL) (Sigma-Aldrich, United Kingdom) was added and the cells were incubated
for 2 h at 37 ºC. Cells were then washed with PBS, treated with DMSO (100 µL/well)
and incubated for 15 min at room temperature. Absorbance was measured at 550 nm
using a VersaMax microplate reader (Molecular Devices, United Kingdom).
Measurement of cellular triglyceride content
Cells (1 × 105 cell/mL) were incubated overnight in a 24-well plate and then treated
with different ratios of omega fatty acids for 24, 48 and 72 h. Following the treatments,
intracellular triglyceride content was determined by using EnzyChrom™ triglyceride
assay kit  (BioAssay Systems,  United States),  as  per  manufacturer’s  instructions.
Triglyceride content was normalised to protein content, as determined by using Bio-
Rad protein assay kit according to manufacturer’s instructions. Data were expressed
as mg triglyceride/mg protein.
Measurement of intracellular ROS levels
Cells (1 × 104 cells/ 200-µL DMEM) were incubated overnight in a 96-well plate. Then,
the cells were treated with different ratios of omega fatty acids for 30 min, 1 h, 2 h, 3 h,
6  h  and  24  h.  Following  this,  the  cells  were  treated  with  1  µmol  2′,7′-
dichlorofluorescein  diacetate  (Sigma-Aldrich,  United  Kingdom)  (in  PBS)  and
incubated at 37 ºC for 45 min. Fluorescence intensity was measured at an excitation of
485 nm and an emission of 535 nm by using FLUOstar OPTIMA (Jencons-PLS, United
Kingdom). Fluorescence levels were expressed as percentage of the control.
Examination of mitochondrial respiratory function
The mitochondrial oxygen consumption rate (OCR) was evaluated using the XF Cell
Mito Stress Test Kit as per manufacturer’s instructions (Agilent Technologies, Craven
Arms, United Kingdom). Plates were analysed using the Seahorse XF24 (Agilent
Technologies, United Kingdom)., Essentially, cells (1.5 × 104  cells/100 µL DMEM)
were seeded in a SeaHorse 24-well culture microplate. After incubation for 2 h at 37
ºC and 5% CO2, 150 µL of DMEM (10% FCS) was added to the cells. The cells were re-
incubated overnight at 37 ºC and 5% CO2. The following day, cells were treated with
various AA:DHA ratios in 10% FCS DMEM and plates were incubated at 37 ºC and
5% CO2  for 24 h. The next day, Seahorse XF Assay Medium without glucose was
supplemented with sodium pyruvate (1 mmol) and glucose (25 mmol) and the pH
was  adjusted  to  7.4.  Cells  were  washed  twice  with  this  Seahorse  medium  and
incubated at 37 ºC and 0% CO2 for 45 min. To monitor the OCR of the cells, SeaHorse
XF analyser was calibrated with the sensor cartridge containing Mito stress drugs
FCCP (1 µmol), an uncoupling agent; oligomycin (1 µmol) for ATP synthase inhibition
and  an  antimycin/Rotenone  mixture  (0.5  µmol)  for  inhibition  of  oxidative
phosphorylation and electron transfer, respectively. Following the measurement of
OCR,  1%  Triton  X-100  were  used  to  lyse  the  cells  and  the  protein  content  was
determined by using Bio-Rad protein assay kit. Seahorse cell Mito stress parameters
were calculated following manufacture’s protocol, normalized to protein content and
the data were expressed relative to control.
Western Blotting determination of protein expression
Cells were treated with different ratios of omega fatty acids for 24 h.  Then, total
cellular protein was extracted using 1% Triton X-100 in PBS containing a protease
inhibitor cocktail tablet and the protein concentration was determined by using Bio-
Rad protein  assay kit,  as  per  manufacturer's  instructions  (Bio-Rad Laboratories,
United Kingdom). Protein (20-40 µg) was separated on 10% SDS-PAGE gels (Thermo
Scientific  Pierce,  United  Kingdom)  by  electrophoresis  for  90  min  at  120  V  and
transferred onto a nitrocellulose membrane (0.45 µm) for 1 h at 350 A. Membranes
were blocked with 1% BSA, except when confirming β-actin where 5% BSA was used.
The proteins  examined were  SCD1 (1:4000)  (Abcam,  United Kingdom),  PPAR-α
(1:2000) (Abcam, United Kingdom), CB1, (1:4000) (Santa Cruz Biotechnology, United
Kingdom) CB2 (1:2000)  (Abcam, United Kingdom),  and β-actin (1:4000)  (Abcam,
United Kingdom). West PICO Chemiluminescent Substrate (ThermoFisher, United
Kingdom) was used for detection and the X-ray films were scanned on a Bio-Rad GS-
800  Calibrated  Densitometer  (Bio-Rad,  United  Kingdom) [23,24].  During  post-
densitometry analysis, data were expressed relative to corresponding β-actin levels
and compared to the experimental control.
Statistical analysis
The statistical methods of this study were reviewed by Dr Claire Robertson, Senior
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Lecturer in Nutritional Epidemiology, University of Westminster.
As variances were equal between groups, a one-way ANOVA followed by post-hoc
analysis by Tukey's test was used to assess differences between omega fatty acid
ratios and control treated groups. Data analysis was conducted using SPSS version
23.0  Data  were  expressed  as  the  mean ±  SEM,  n  =  3-5,  and where  P  ≤  0.05  was
considered significant.
RESULTS
High omega-6:3 (AA:DHA) ratio induced lipotoxicity
After 24 h, high AA:DHA ratios reduced mitochondrial activity, when compared to
the untreated control [15:1 by 17% (P < 0.05) and 25:1 by 82% (P < 0.01)] (Figure 1A).
Furthermore, high AA:DHA ratio (15:1) induced reduction in activity when compared
to the moderate ratios of 1:1 (by 22%, P < 0.05) and 4:1 (by 20%, P < 0.01) (Figure 1A).
A similar pattern was induced by the high 25:1 ratio, which showed reduced activity
in comparison to 1:1 (by 83%, P < 0.05) and 4:1 (by 83%, P < 0.01) ratios (Figure 1A).
After 48 h, only the 25:1 ratio caused a significant reduction in activity compared to
the control, 1:1, and 4:1 by 51%, 54%, 56%, respectively (P < 0.01) (Figure 1B). At 72 h,
both the high ratios (15:1 and 25:1) reduced mitochondrial activity. The 15:1 ratio
markedly reduced mitochondrial activity in comparison to the control (by 91%, P <
0.01), 1:1 (by 92%, P < 0.01) and 4:1 (by 91, P < 0.01) ratios (Figure 1C). Similarly, the
25:1 ratio reduced mitochondrial activity in comparison to the control (by 90%, P <
0.01), 1:1 (by 91%, P < 0.01) and 4:1 (by 89%, P < 0.01) (Figure 1C).
High omega-6:3 (AA:DHA) ratio- increased lipid accumulation
Significant  changes  in  cellular  lipid  were  observed  after  24  h.  Interestingly,  in
comparison to the untreated control, the 1:1 ratio reduced triglyceride accumulation
(by 43%, P = 0.01), whereas a high 25:1 ratio elevated intracellular triglyceride levels
(by 42%, P < 0.01) (Figure 2A). Importantly, in comparison to treatment with 1:1 ratio,
lipid concentration was elevated with 4:1 ratio (by 75%, P < 0.05), 15:1 ratio (by 53%, P
< 0.05), and with 25:1 ratio (by 41%, P < 0.01) (Figure 2A).
Similarly, after 48 h, treatments with 4:1, 15:1 and 25:1 ratios increased triglyceride
accumulation in comparison to the control (by 117%, P = 0.01; 177%, P < 0.05; and
91%, P < 0.05, respectively), and also when compared to treatment with 1:1 ratio (by
91%,  P  <  0.01;  143%,  P  <  0.01  and  68%,  P  <  0.05,  respectively)  (Figure  2B).  No
significant alterations in triglyceride accumulation were observed after 72 h (Figure
2C).
High omega-6:3 (AA:DHA) ratio reduced PPAR-α and increased SCD1
Molecular mediators of lipid metabolism were examined. When compared to the
untreated control, SCD1 expression increased significantly following treatments with
15:1  and  25:1  ratios  [by  22%  and  33%,  (P  <  0.05),  respectively]  (Figure  3A).
Furthermore,  treatment with 25:1 ratio increased its  expression compared to the
moderate 1:1 ratio treatment (by 35%, P < 0.05) (Figure 3A).
PPAR-α expression significantly decreased with 15:1 ratio when compared with the
control and 1:1 treatments (by 29% and 35%; P < 0.05, respectively) (Figure 3B). This
trend of decreasing expression was more evident following treatment with the 25:1
ratio, when compared to control and 1:1 treatments (by 35%, P < 0.05 and 40%, P <
0.01, respectively) (Figure 3B). No changes in SREBP1-c expression was observed at all
ratios (Figure 3C).
High omega-6:3 (AA:DHA) ratio altered CB expression
Following treatment with 1:1 ratio, CB1 expression increased only subtly compared to
the control (by 17%, P < 0.05), but the increment was significantly greater at 25:1 ratio
(by 31%, P  < 0.01) (Figure 3D). CB2 expression showed no significant alterations,
except with 15:1 ratio, which reduced CB2 expression compared to the control (P <
0.01) (Figure 3E), although the 25:1 ratio which showed a general increased expression
when compared to all ratios.
High omega-6:3 (AA:DHA) ratio increased ROS production
In comparison to the untreated control, ROS levels significantly increased with all
ratios after 30 min (1:1 and 15:1 by 74%, P  < 0.05; 4:1 and 25:1 by 88% and 104%,
respectively, P < 0.01) (Figure 4A). No major differences were observed in ROS levels
between the moderate ratios (1:1 and 4:1) and high ratios (15:1 and 25:1).
Similarly, after 1 h, while ROS levels increased following treatments with 15:1 ratio
(by 117%; P < 0.01) and 25:1 ratio (by 96%; P < 0.01), treatments with 1:1 and 4:1 ratios
did  not  cause  any  significant  change  compared  to  the  control  (Figure  4B).
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Figure 1
Figure 1  Effect of arachidonic acid: docosahexaenoic acid ratios on mitochondrial activity. A-C: VL17-A cells were treated with different ratios of arachidonic
acid: docosahexaenoic acid and mitochondrial activity was assessed after 24 h (A), 48 h (B) and 72 h (C). aP < 0.05 and bP < 0.01 compared to control; cP < 0.05 and
dP < 0.01 compared to 1:1 ratio; eP < 0.05 and fP < 0.01 compared to 4:1 ratio. Data is presented as mean ± SE (n = 3). AA: Arachidonic acid; DHA:
Docosahexaenoic acid.
Interestingly, treatment with high ratios (15:1 and 25:1) significantly elevated ROS
levels compared to the moderate ratios of 1:1 and 4:1. Specifically, when compared
with the 1:1 and 4:1 ratio, the 15:1 ratio increased ROS levels by 123% (P < 0.01) and
75% (P < 0.01) respectively, and 25:1 ratio increased ROS levels by 102% (P < 0.01) and
58% (P < 0.01), respectively (Figure 4B).
After 2 h, in comparison to 1:1 ratio, ROS levels decreased with the 4:1 ratio (by
17% P < 0.01) (Figure 4C). However, in comparison to the control and 4:1 ratio, ROS
levels were significantly elevated with the high 15:1 ratio (by 31%, P < 0.05 and 58% P
< 0.01, respectively). These were also high with the 25:1 treatment when compared
with the 4:1 treatment (by 30% P < 0.05) (Figure 4C). No effect was observed after 3 h,
6 h or 24 h for all ratios (data not shown for brevity).
High omega-6:3 (AA:DHA) ratio disrupted mitochondrial functions
Elevation  in  AA:DHA ratios  caused a  gradual  and significant  decrease  in  basal
respiration when compared to control [1:1 (by 20%, P < 0.05); 4:1 (by 25%, P < 0.01);
15:1 (by 38%, P < 0.01); and 25:1 (by 40%, P < 0.01)] (Figure 5A). Similar results were
observed when compared to treatment with 1:1  ratio,  whereby basal  respiration
significantly reduced with 15:1 and 25:1 ratios (by 19% and 21%, respectively, P <
0.05) (Figure 5A).
Maximal respiration decreased gradually with 1:1, 4:1, 15:1 and 25:1 ratios (by 35%,
44%, 54%, and 56% (P < 0.01), respectively) (Figure 5B). Spare respiratory capacity
showed a similar pattern of significant reductions (by 52%, 56%, 67%, and 68% (P <
0.01) over the increasing AA/DHA ratios (Figure 5C). ATP production significantly
reduced with elevation in AA:DHA 1:1, 4:1, 15:1, 25:1 ratios (by 25%, 33%, 44% and
41%, respectively, (P < 0.01)) (Figure 5D). Proton leak decreased significantly with
high omega ratio of 15:1 (by 41% P < 0.01) compared to control, and with 25:1 by 50%
and 31% (P < 0.01), when compared to control and 1:1 ratio, respectively (Figure 5E).
DISCUSSION
NAFLD is  recognized as  a  growing global  epidemic  affecting 10%-35% of  adult
population in the world[25],  with highest prevalence in the Middle East and South
America[26]. In the US, it affects at least 18 % of the adult population and 90 % of obese
people with an overall prevalence of 35 %[26].  Moreover, a recent epidemiological
study demonstrated an exponential increase in NAFLD burden in the United States[27].
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Figure 2
Figure 2  Effect of arachidonic acid: docosahexaenoic acid ratios on intracellular triglyceride accumulation. A-C: VL17-A cells were treated with different
ratios of arachidonic acid: docosahexaenoic acid for 24 h (A), 48 h (B) and 72 h (C). Intracellular triglyceride levels were measured and normalised to cellular protein
content. aP < 0.05 and bP ≤ 0.01 compared to control; cP < 0.05 and dP ≤ 0.01 compared to 1:1 ratio. Data is presented as mean ± SE (n = 5). AA: Arachidonic acid;
DHA: Docosahexaenoic acid.
Predicted to “emerge as the leading cause of end-stage liver disease”[4], NAFLD calls
for a thorough understanding of the underlying mechanisms.
High dietary intake of omega-6 fatty acids (mainly in processed foods) and/or
lower intake of omega-3 fatty acids has been implicated in the development of fatty
liver[7,28,29]. In vivo and in vitro studies have demonstrated the significance of omega-3
fatty  acids  in  regulating  lipid  accumulation,  fatty  acid  oxidation  and  reversing
steatosis-induced mitochondrial dysfunction[30,31]. The significance of balanced omega-
6:3 ratio was more evident in recent trials where treatment of NAFLD patients with
omega-3 fatty acids such as eicosapentaenoic acid (EPA) or DHA reduced steatosis
and liver enzymes[32,33]. However, the underlying pathological mechanisms under high
omega-6: omega-3 states remain unclear. It is pivotal to understand these mechanisms
to identify biochemical pathways and molecular targets that may help in formulating
preventative and therapeutic interventions to halt,  decelerate or reverse NAFLD
progression.
Accordingly, here, we investigated the effect of increasing ratios of omega-6 (AA):
omega-3  (DHA)  fatty  acids  on  various  cellular  parameters  in  VL-17A cells.  We
compared the effects of high AA: DHA ratios with untreated control and with the
effects induced by healthy ratios of 1:1 and 4:1. The aim was to understand these
altered mechanisms that prevail during high omega-6: omega-3 states and relate these
to NAFLD pathogenesis.
High omega-6: omega-3 ratio (AA:DHA) caused lipotoxicity and promoted steatosis
High AA:DHA ratios  significantly  reduced mitochondrial  activity  and thus  cell
viability (Figure 1). This indicates lipotoxicity due to high omega-6 (AA) content, as
its immediate metabolites are strongly proinflammatory[7]. The majority of studies
with fatty acid treatment using in vitro models of NAFLD are based on a single 12-48
h time point to enable lipid accumulation and its subsequent detection. Our data
showed a marked increase in triglyceride accumulation after 24 h and also at 48 h, in
comparison to the untreated control and healthy ratios (1:1 and 4:1) (Figure 2), which
is  similar  to  other  models  of  NAFLD  where  steatosis  was  reported  in  primary
hepatocytes after 16-24 h treatment with oleic acid[34], palmitic acid[35] or stearic acid[36].
However, after 72 h lipid concentration was normal. This suggests a biological
response to high AA:DHA ratios in the short-term. Repeating the treatment again or a
sustained period of omega fatty acids in the growth media, would provide further
support  that  the response is  biological  rather than an acute transient  effect.  Our
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Figure 3
Figure 3  Effect of arachidonic acid: docosahexaenoic acid ratios on mechanistic mediators of lipid metabolism. A-E: VL17-A cells were treated with different
ratios of arachidonic acid: docosahexaenoic acid for 24 h. Following this, the expression of several proteins that modulate lipid metabolism were examined, namely,
SCD1 (A), PPAR-α (B), SREBP1c (C), CB1 (D) and CB2 (E). aP ≤ 0.05 and bP ≤ 0.01 compared to control; cP < 0.05 and dP < 0.01 compared to 1:1 ratio; eP < 0.05
compared to 4:1 ratio. Data is presented as mean ± SE (n = 3-4). AA: Arachidonic acid; DHA: Docosahexaenoic acid.
findings are generally in line with previous studies where high-fat diet with various
AA:EPA and AA:DHA ratios (1:1, 5:1, 10:1 and 20:1) increased hepatic phospholipid
AA:eicosapentaenoic  acid  and  AA:DHA  in  a  dose  dependent  manner,  mildly
influenced inflammatory signaling, as well as key lipogenic regulators[37],  though
lowering the ratio did not prevent lipid accumulation[37]. Despite the latter study there
is substantial evidence that the omega 6:3 ratio is an important contributory factor in
NAFLD development.  Recently NAFLD co-twin studies showed that the hepatic
omega 6:3 ratio is significantly greater when liver fat > 5% suggesting the impact of
diet independent of genetics plays a role in NAFLD occurrence[38]. In other models of
NASH where animals were fed a Western diet, omega 6 lipid concentrations were
increased in hepatic membranes, whereas omega 3 lipid concentrations were reduced;
inflammatory markers were also increased, and this effect was reversed when animals
were given DHA[39]. Whereas with other models of fatty liver, lowering the omega 6:3
ratio attenuated gut and liver injury suggesting that a normal ratio is important in
fatty liver reversal[40].
Under physiological conditions, free fatty acids fuel oxidative stress and produce
inflammatory cytokines that induce cell injury. Therefore, their esterification and
deposition in the liver as triglycerides provide a protective mechanism to prevent
additional liver damage[2]. Thus, it is possible that the high AA:DHA-ratio-induced
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Figure 4
Figure 4  Effect of arachidonic acid: docosahexaenoic acid ratios on ROS production. A-C: VL17-A cells were treated with different ratios of arachidonic acid:
docosahexaenoic acid for 30 min (A), 1 h (B) and 2 h (C), and ROS levels were measured. aP < 0.05 and bP < 0.01 compared to control; dP < 0.01 compared to 1:1;
eP < 0.05 and fP < 0.01 compared to 4:1 ratio. Data is presented as mean ± SE (n = 3). AA: Arachidonic acid; DHA: Docosahexaenoic acid.
elevated triglyceride concentration observed here (Figure 2) are a manifestation of a
counter-protective response against the high omega-6: omega-3 ratio. However, it is
also  possible  that  this  triglyceride  accumulation  may  contribute  to  fatty  liver
pathogenesis because excessively increased cellular triglycerides may dysregulate
lipid metabolism, promote steatosis and insulin resistance, elevate gluconeogenesis
and decrease glycogenesis[41].
High omega-6:  omega-3 (AA:DHA) ratio altered mediators of  lipid metabolism:
mechanistic evidence for contribution to NAFLD development
Following  the  confirmation  of  high  AA:DHA-induced  cellular  triglyceride
accumulation (Figure 2), molecular mediators of lipid metabolism were examined.
High dietary fat can increase the synthesis of endocannabinoids, which upregulate the
activity of CB1 and CB2[42-44]. This activation has been implicated in the development
of NAFLD, partly via upregulation of lipogenic enzymes like SCD1 that promote fatty
acid synthesis, and downregulation of PPAR-α expression, which stimulates hepatic
oxidation of fatty acids[7]. Whether high AA:DHA ratio alters these mediators of lipid
metabolism remain unknown. Therefore, we studied the effect of high AA:DHA ratio
on  the  expression  of  SCD1  to  understand  its  lipogenic  capacity  and  PPARα  to
examine its potential for fatty acid oxidation.
Here,  high  AA:DHA ratio  increased SCD1 expression  (Figure  3A),  indicating
elevation in lipogenic capacity. This is consistent with a previous study where mice
fed a diet with high omega-6: omega-3 ratio demonstrated increased expression of
SCD1[45]. The increase in SCD1 expression could be due to direct binding of liver X
receptor (it’s activator) or due to activation of its transcription factor SREBP1c[30,46,47].
Conversely other studies have reported a decrease in lipid droplet levels combined
with a downregulation in SCD1 & SREBP levels following DHA treatment for 12 h in
primary hepatocytes[48],  although here no significant alterations were observed in
SREPB1c  expression  (Figure  3C).  Finally,  high  AA:DHA  ratio  reduced  PPARα
expression (Figure 3B),  which indicated reduced capacity of  fatty acid oxidation
under these conditions. Elevation in SCD1 in combination with a reduction in PPARα
expression may partly explain the mechanisms underlying fatty liver development
under high omega-6:3 environment.
We also examined the expression of CB1 and CB2 under conditions of high omega-
6:3 ratio to evaluate its stimulatory potential for fatty acid synthesis. As hypothesized,
CB1 expression significantly increased following treatment with a high 25:1 ratio
(Figure 3D). Although CB1 activation via LXR is thought to upregulate SREBP1c[49],
our data suggested no direct correlation. This is similar to studies in HepG2 cells
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Figure 5
Figure 5  Effect of arachidonic acid: docosahexaenoic acid ratios on mitochondrial respiratory functions. VL17-A cells were treated with different ratios of
arachidonic acid: docosahexaenoic acid for 24 h and various parameters that determine the mitochondrial respiratory functions were examined. A: Elevation in
AA:DHA ratios caused a gradual and significant decrease in basal respiration when compared to control. Similar results were observed when compared to treatment
with 1:1 ratio, whereby basal respiration significantly reduced with 15:1 and 25:1 ratios; B: Maximal respiration decreased gradually with 1:1, 4:1, 15:1 and 25:1 ratios
(by 35%, 44%, 54%, and 56%, respectively); C: Spare respiratory capacity showed a similar pattern of significant reductions (by 52%, 56%, 67%, and 68% over the
increasing AA/DHA ratios; D: ATP production significantly reduced with elevation in AA:DHA 1:1, 4:1, 15:1, 25:1 ratios (by 25%, 33%, 44% and 41%, respectively); E:
Proton leak decreased significantly with high omega ratio of 15:1 compared to control, and with 25:1 by 50% and 31%, when compared to control and 1:1 ratio,
respectively. aP < 0.05 and bP < 0.01 compared to control; cP < 0.05 and dP < 0.01 compared to 1:1 ratio. Data is presented as mean ± SE (n = 4-5). AA: Arachidonic
acid; DHA: Docosahexaenoic acid.
where  CB1  agonist  did  not  significantly  alter  the  expression  of  SREBP-1c[50].
Furthermore, liver CB1 mRNA expression negatively correlated with hepatic PPARα
expression, but not SREBP1c in patients with NASH[51], which is similar to the pattern
observed  in  this  study.  Furthermore,  inhibition  of  CB1  receptors  has  shown  to
improve lipogenesis in vitro[52]. Since high omega-6:3 ratio promotes obesity via both,
AA-derived eicosanoid metabolites and over-activation of the cannabinoid system[10],
it is possible that cannabinoid-independent pathways may sufficiently operate for
high omega-6-induced fatty acid synthesis or other regulators may predominate. For
example,  CB1  receptors  could  be  regulated  by  SREBP-1c,  ChREBP and LXRs[52].
Overall, these findings suggest a role for CB1 activation under high omega 6:3 ratios
leading to enhanced steatosis.
Except for 25:1 ratio, CB2 receptors showed moderately reduced expression when
compared to control (Figure 3E), which was significantly lower following treatment
with 15:1 ratio (Figure 3E). While some studies suggest that CB2 activation promotes
NAFLD, other studies indicate a preventative role[42,53,54]. However, other studies have
also reported a strong downregulation of CB2 gene expression in human hepatocytes
following fatty acid treatment[50]. Further studies using agonists/antagonists of the
CB1 and 2  receptors  are  required to  determine their  exact  role  in  NAFLD deve-
lopment.
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High AA:DHA ratio altered redox biology
Increased oxidative stress is one of the key characteristics of NAFLD, which promotes
tissue injury[55].  There is no data yet on the effect of high AA:DHA ratios on ROS
production. Here, we observed that ROS levels increased with all AA:DHA ratios
within 30  min and generally  beyond this  time when compared to  the  untreated
control (Figure 4). Moreover, high AA:DHA ratios elevated ROS levels in comparison
to the healthy ratios of 1:1 and 4:1 at 1 h and 2 h (Figure 4B, 4C), clearly indicating the
impact of high AA:DHA ratio on ROS production. After 3, 6 or 24 h no increase in
ROS production occurred, supporting the point that incubation time is an important
aspect  in  this  model.  This  is  similar  to  other  models  of  NAFLD,  where  ROS
production was significantly increased after 30 min of palmitic acid treatment[56].
Alternatively, after 30 min incubation with DHA ROS levels were lower than steatotic
HepG2 cells[31]. However, other studies have shown an increase in ROS levels after a
single measurement at 24 h of palmitic acid treatment[57,58]. This highlights the variance
in time dependent ROS effects depending on the model used, although the net effect
is increased oxidative stress.
The high ROS effect could be attributed to the high AA content in the AA:DHA
ratio, which acts as a strong inhibitor of complexes I and III in the respiratory chain[59].
This  would hinder  electron flow through the  respiratory chain causing electron
leakage from these complexes and reduce mitochondrial membrane potential, thereby
promoting ROS production[60]. However, other sources of ROS could be via CYP2E1
metabolism of AA[61]. Interestingly the high 15:1 ratio maintained the high levels of
ROS after 1 h and 2 h, whereas the lower ratios of 1:1 and 4:1 either restored ROS
levels to that of control or decreased ROS production (Figure 4B, 4C). This restoration
could be due to fatty acid oxidation and the capability of the respiratory chain to
handle the excess electrons released when the ratio was in the recommend healthy
range.
High AA:DHA ratio disrupted mitochondrial functions
Disturbed  mitochondrial  function  has  been  implicated  in  the  pathogenesis  of
NAFLD[55].  A 30%-40% decrease in the respiratory rate along with mitochondrial
uncoupling  has  been  reported  in  obese  patients  with  NASH[62].  Therefore,  we
investigated the impact of high AA:DHA ratio on several mitochondrial functions. We
observed that high AA:DHA ratios (15:1 and 25:1)  decreased basal  and maximal
respiration, spare respiratory capacity, proton leak and ATP production (Figure 5).
The mechanisms responsible for this could relate to destabilization of cytochrome C
affecting  electron  flow  and  ultimately  ATP  synthesis[63],  the  direct  uncoupling
protonophoric ability of fatty acids which impairs ATP synthesis[63] or the opening of
the mitochondrial permeability transition pores causing mitochondrial membrane
potential loss leading to mitochondrial swelling and cell death[64]. These findings are
similar to animal studies with fatty liver, where a reduction in the respiratory rate,
increased oxidative stress, and reduction in complex I activity was observed[65-67].
Further work is required to elucidate the exact damaging effect of omega 6 fatty
acids,  however,  it  is  important  to  state  that  not  all  omega  6  fatty  acids  are
harmful/proinflammatory  or  omega  3  fatty  acids  are  protective,  and  thus  it  is
important not to generalize fatty acids, but to focus on specific fatty acids.
Limitations of the study
In terms of study limitations, there are a number of caveats. Firstly, measurement of
hepatic  phospholipid AA: eicosapentaenoic acid and AA:DHA, the SCD activity
which measures the conversion of fatty acids to lipids, and mRNA levels of fatty acid
synthase and acetyl-CoA carboxylase would confirm the lipid changes following high
omega 6:3 ratio supplementation in HepG2 cells. As we only observed ROS induced
injury over a short period of time, other markers of oxidative stress such as lipid
peroxides and protein carbonyls, combined with markers of endoplasmic reticulum
stress, such as c-Jun N-terminal kinase, and measurement of AA metabolites such as
leukotrienes would provide further weighting behind the observations. The precise
role of CB1 and CB2 receptor activation requires further elucidation; application of
receptor agonists/antagonists would provide insight into lipogenesis under high
omega ratios.  Finally,  it  will  be  important  to  examine the effect  of  adding DHA
directly to the cells after omega treatment to ascertain whether lipid accumulation can
be reversed. Nutritional interventions that focus on particular omega 3 fatty acids is of
interest  due to the growing body of  evidence showing reversal  of  NAFLD upon
treatment with omega fatty acids.
In conclusion, this is the first study using high to normal omega 6:3 ratios in VL17A
(HepG2 cells). These cells overexpress CYP2E1 which can metabolize AA, thus they
resemble metabolic changes occurring in hepatocytes. In addition, the majority of in
vitro NAFLD models of fatty acid treatment are based on a single 12-48 h time point to
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enable lipid accumulation and its subsequent detection. As far as we are aware no
studies have reported a time course effect of omega fatty acids from 24 to 72 h in
HepG2  cells  studying  lipid  accumulation  or  ROS  production,  combined  with
lipogenic markers.
In  summary,  high omega 6:3  ratios  of  AA:DHA stimulated lipid synthesis  by
reducing fatty acid oxidation (decrease in PPAR alpha expression), increased CB1
expression, and also promoting the conversion of unsaturated fatty acids to saturated
fatty acids via SCD1 with the net effect of lipid accumulation in human hepatoma
(VL17A) cells. High ratios also led to increased oxidative stress, which is an important
feature in the inflammatory state. Lipids synthesised in the liver are thus susceptible
to oxidative attack by ROS. The loss of mitochondrial function possibly due to ROS or
direct  uncoupling effect  of  AA also promotes  cell  death,  thus compounding the
inflammatory effects. These results suggest that high omega 6:3 ratios can possibly
lead to key steps in the progression from fatty liver to NASH.
ARTICLE HIGHLIGHTS
Research background
Fatty liver disease is due to the consumption of excess dietary calories as well as a disruption in
lipid metabolism and leads to the condition non-alcoholic fatty liver disease (NAFLD). The
prevalence of NAFLD in most Western societies ranges from 20%-50%. Whilst the mechanisms
for NAFLD development are complex, NAFLD patients show higher levels of omega-6 fatty
acids than omega 3 fatty acids. Omega 6 fatty acids are known to be damaging to the liver
causing toxicity, but their precise role in the pathology of NAFLD is not understood. This was an
important question since NAFLD is a major public health problem and alternative interventions
are required.
Research motivation
The  main  treatment  options  for  NAFLD  are  dietary  and  lifestyle  changes.  We  therefore
addressed the question of how diet increases the risk of NAFLD, specifically the role of omega 6
fatty acids in relation to omega 3 fatty acids. Since this is a modifiable risk factor it is important
to understand how high levels of omega 6 fatty acids can damage the liver and whether omega 3
fatty acids can minimise/reduce this damage. This will lead to improved understanding of
NAFLD development and new therapeutic treatment options.
Research objectives
This research study aimed to understand the role of high omega 6:omega 3 ratios in a hepatic cell
line  model  of  NAFLD,  thus  allowing  its  contribution  to  lipotoxicity,  oxidative  stress  and
mitochondrial function to be investigated. These findings may help explain the progression from
fatty liver to the inflammatory state, non-alcoholic steatohepatitis.
Research methods
Human hepatoma cells, named VL-17A were treated with a range of high and normal ratios of
omega-6: omega-3 fatty acids [arachidonic acid (AA): docosahexaenoic acid (DHA)]. These novel
experiments examined the effect of these ratios on mitochondrial function, oxidative stress and
viability. Changes in lipid accumulation combined with the expression of relevant lipogenic
proteins was also assessed.
Research results
High omega-6:omega-3 (AA:DHA) ratio altered several processes in VL-17A cells. It reduced
mitochondrial activity indicating lipotoxicity, increased triglyceride accumulation, elevated
reactive oxygen species levels and interrupted several mitochondrial functions. Moreover, our
study provided mechanistic data as to which of these detrimental effects may be mediated under
high omega-6: omega-3 conditions and contribute to NAFLD development. Specifically, these
include  increased  expression  of  stearoyl-CoA  desaturase  and  decreased  expression  of
peroxisome proliferator-activated receptor alpha. Also, elevation in cannabinoid receptor CB1
expression was observed that has been positively associated with fatty liver development. The
present study clearly demonstrates the potential long-term consequences of high omega-6:3
ratios in NAFLD development.
Research conclusions
The  conclusions  from  this  study  strongly  suggest  that  high  omega  6:omega  3  ratios  are
detrimental to liver function, promoting an oxidant environment combined with higher amounts
of lipid accumulation. These features are the hallmark of NAFLD indicating that altered omega
6:3 fatty acid ratios play an important role in NAFLD development and progression. Therefore,
the original hypothesis was confirmed which can form the basis for further mechanistic studies
examining other omega 6 fatty acids in NAFLD pathogenesis. The study also supports various
studies where clinical interventions using omega 3 fatty acids have been utilised for NAFLD
treatment.
Research perspectives
Whilst further work is required, when investigating patients with NAFLD, measurement of
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circulating omega fatty acids should be considered. This may lead to the possibility of treating
patients with omega 3 fatty acids. Other interventions that ameliorate oxidative stress and which
improve mitochondrial function also require future research as this may lead to the reversal of
NAFLD.
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